Mao Richeng相关文献与解析，生知库 | 链接生命科学的每一步

Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China

比较400毫升或800毫升细菌计数粪便微生物移植治疗复发性肝性脑病的疗效和安全性：一项在中国开展的多中心前瞻性随机对照试验

Zou, Pengfei; Bi, Yunjiao; Tong, Zhaowei; Wu, Tao; Li, Qiang; Wang, Kai; Fan, Yuchen; Zhao, Dan; Wang, Xin; Shao, Hui; Huang, Haijun; Ma, Suping; Qian, Yunsong; Zhang, Guoqiang; Liu, Xiao; Jin, Qiaofei; Ru, Qingjing; Qian, Zhiping; Sun, Wei; Chen, Qiang; You, Liying; Wang, Fang; Zhang, Xiaoting; Qiu, ZhenXiong; Lin, Qing; Lv, Jiaojian; Zhang, Yongping; Geng, Jiawei; Mao, Richeng; Liu, Jinfeng; Zheng, Yubao; Ding, Feng; Wang, Hui; Gao, Hainv

微生物学

神经科学

发表日期：2024

文献求助收藏

Etiology and Prognostic Criteria for Liver Failure in Southeast China: A Multicenter Retrospective Cohort Study Between 2018 and 2020

中国东南地区肝衰竭的病因及预后标准：一项2018年至2020年多中心回顾性队列研究

期刊:Gastroenterology Research and Practice

影响因子:1.4

doi:10.1155/grp/5512889

Lyu, Chunyan; Han, Jun; Kang, Naling; Zeng, Dawu; Davgadorj, Chantsalmaa; Ge, Lina; Zhou, Meifang; Mao, Richeng; Yan, Yan

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies

SARS-CoV-2 Omicron 变异株中不断演变的刺突蛋白突变有助于其逃避突破性感染后获得的抗体。

期刊:Cell Discovery

影响因子:12.5

doi:10.1038/s41421-023-00584-6

Chen, Shiqi; Huang, Zehong; Guo, Yue; Guo, Huilin; Jian, Lijuan; Xiao, Jin; Yao, Xiangyang; Yu, Hai; Cheng, Tong; Zhang, Yali; Guan, Ming; Mao, Richeng; Zhang, Jiming; Xia, Ningshao; Yuan, Quan

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation

治疗结束时的抗-HBs水平和HBeAg状态可确定PEG-IFN停药后HBsAg清除的持久性。

期刊:Frontiers in Cellular and Infection Microbiology

影响因子:4.8

doi:10.3389/fcimb.2023.1120300

Guo, Yifei; Han, Jiajia; Zhang, Yongmei; Jin, Chengmeng; Zhang, Yao; He, Jingjing; Chen, Shiqi; Guo, Yue; Lin, Yanxue; Li, Fahong; Yang, Feifei; Shen, Zhongliang; Mao, Richeng; Zhu, Haoxiang; Zhang, Jiming

发表日期：2023

文献求助收藏

In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study

慢性肾脏病患者感染SARS-CoV-2 omicron变异株后院内不良结局及危险因素：一项单中心回顾性研究

期刊:BMC Infectious Diseases

影响因子:3

doi:10.1186/s12879-023-08620-2

Guo, Yue; Guo, Yifei; Ying, Huajian; Yu, Weien; Chen, Shiqi; Zhang, Yao; Zhang, Shenyan; Lin, Yanxue; Sun, Feng; Zhang, Yongmei; Yu, Jie; Ma, Ke; Qin, Lunxiu; Long, Feng; Zhu, Haoxiang; Mao, Richeng; Xue, Jun; Zhang, Jiming

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients

比较聚乙二醇干扰素α联合富马酸替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎患者的疗效

期刊:Infection and Drug Resistance

影响因子:2.9

doi:10.2147/IDR.S411183

He, Jingjing; Guo, Yifei; Zhang, Yao; Han, Jiajia; Chen, Jingwen; Jia, Yidi; Ma, Zhenxuan; Wu, Jingwen; Zhang, Shenyan; Li, Fahong; Mao, Richeng; Zhang, Jiming

肝炎

发表日期：2023

文献求助收藏

Plasma S100A8 and S100A9 Are Strong Prognostic Factors for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure

血浆S100A8和S100A9是乙型肝炎病毒相关急性加重型慢性肝衰竭的强预后因素

期刊:Canadian Journal of Gastroenterology and Hepatology

影响因子:2.3

doi:10.1155/2023/6164611

Zhang, Yao; Zhang, Xueyun; Han, Jiajia; Guo, Yifei; He, Jingjing; Yang, Feifei; Mao, Richeng; Huang, Yuxian; Zhang, Jiming

Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs

慢性乙型肝炎患者长期接受核苷（酸）类似物治疗后低水平病毒血症的患病率及相关因素

期刊:Turkish Journal of Gastroenterology

影响因子:1.6

doi:10.5152/tjg.2023.21978

Han, Jiajia; Guo, Yifei; Zhang, Xueyun; Zhang, Yao; Sun, Jian; He, Jingjing; Mao, Richeng; Huang, Yuxian; Zhang, Jiming

Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing

一种预测侵袭性真菌感染风险和真菌预防时机的新型模型

The host gene CSTF2 regulates HBV replication via HBV PRE-induced nuclear export.

宿主基因 CSTF2 通过 HBV PRE 诱导的核输出来调控 HBV 复制

Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China

比较400毫升或800毫升细菌计数粪便微生物移植治疗复发性肝性脑病的疗效和安全性：一项在中国开展的多中心前瞻性随机对照试验

Etiology and Prognostic Criteria for Liver Failure in Southeast China: A Multicenter Retrospective Cohort Study Between 2018 and 2020

中国东南地区肝衰竭的病因及预后标准：一项2018年至2020年多中心回顾性队列研究

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies

SARS-CoV-2 Omicron 变异株中不断演变的刺突蛋白突变有助于其逃避突破性感染后获得的抗体。

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation

治疗结束时的抗-HBs水平和HBeAg状态可确定PEG-IFN停药后HBsAg清除的持久性。

In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study

慢性肾脏病患者感染SARS-CoV-2 omicron变异株后院内不良结局及危险因素：一项单中心回顾性研究

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients

比较聚乙二醇干扰素α联合富马酸替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎患者的疗效

Plasma S100A8 and S100A9 Are Strong Prognostic Factors for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure

血浆S100A8和S100A9是乙型肝炎病毒相关急性加重型慢性肝衰竭的强预后因素

Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs

慢性乙型肝炎患者长期接受核苷（酸）类似物治疗后低水平病毒血症的患病率及相关因素